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OBJECTIVES In order to determine a differential benefit from treatment, we compared the long-term
outcome of high-risk versus low-risk patients and evaluated survival free from death or
myocardial infarction at one year.
BACKGROUND Newer anticoagulant strategies during percutaneous coronary intervention have necessitated
a reanalysis of the role of intravenous GP IIb/IIIa inhibitors. The Enhanced Suppression of
the Platelet IIb/IIIa Receptor with Integrilin Therapy trial randomized 2,064 patients
undergoing nonurgent coronary stent implantation to eptifibatide or placebo.
METHODS High-risk characteristics were defined as age 75 years, diabetes, elevated cardiac markers,
ST-segment elevation myocardial infarction within 7 days, or unstable angina within 48 h of
randomization. Age 5 years, absence of diabetes, and any other reason for admission were
considered low risk characterstics.
RESULTS There were 1,018 patients in the high-risk group (50.8% eptifibatide, 49.2% placebo) and
1,045 patients in the low-risk group (50.0% eptifibatide, 50.0% placebo). Baseline
demographics were similar in both groups except for more hypertension (63% vs. 55%,
respectively), peripheral vascular disease (8.2% vs. 5.2%, respectively), prior stroke (5.5%
vs. 3.2%, respectively), and female gender (33% vs. 22%, respectively) in the high-risk
than the low-risk group. At one year, the composite end point of death or myocardial
infarction occurred in 15.89% of placebo patients and 7.99% of eptifibatide patients in the
high-risk group and 9.02% of the placebo and 8.11% of eptifibatide patients in the
low-risk group.
CONCLUSIONS Although eptifibatide treatment improved outcomes for all patients, preprocedural clinical
characteristics can define a subgroup of patients who may derive greatest benefit from its use
during coronary stent placement. (J Am Coll Cardiol 2006;47:715–8) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.075American College of Cardiology Foundation
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rlatelet aggregation plays a central role in the pathogenesis
f coronary thrombosis, which in turn is responsible for the
schemic complications of percutaneous coronary interven-
ion (PCI) (1). Blockade of the platelet surface glycoprotein
GP) IIb/IIIa receptor interrupts the final common pathway
See page 719
f platelet aggregation. Agents that antagonize the platelet
P IIb/IIIa receptor mitigate the thrombosis cascade and as
result offer clinically significant protection against isch-
mic complications of PCI (2–7). Several large randomized
linical trials have clearly indicated that inhibition of platelet
ggregation with platelet GP IIb/IIIa antagonists improve
linical outcomes in patients undergoing elective coronary
ntervention (5–8).
From the *New York Methodist Hospital-Cornell Heart Center, Brooklyn New
ork; and the †Duke Clinical Research Institute, Durham, North Carolina.i
Manuscript received April 8, 2005; revised manuscript received July 29, 2005,
ccepted August 12, 2005.Three GP IIb/IIIa antagonists have been evaluated in
hase III randomized clinical trials and approved for use
2–6). One of these agents, eptifibatide, is an intravenous,
apidly reversible, highly specific competitive inhibitor of
he GP IIb/IIIa receptor. Treatment with eptifibatide has
een shown to reduce both short- and long-term adverse
ardiac events when used for several indications, including
CI (9–11).
The Enhanced Suppression of the Platelet IIb/IIIa Re-
eptor with Integrilin Therapy (ESPRIT) trial evaluated the
fficacy and safety of a novel dosing regimen of eptifibatide
n nonurgent coronary stenting (9). The study demonstrated
37% relative risk reduction in the primary composite end
oint of death, myocardial infarction (MI), need for urgent
arget vessel revascularization, or crossover to GP IIb/IIIa
nhibitor therapy for thrombosis within 48 h compared to
lacebo (6.6% vs. 10.5%; p 0.002). Subsequent substudies
howed that the 48-h and 30-day benefits of eptifibatide in
educing the ischemic complications of PCI with stent
mplantation were sustained to at least one year (11).
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High-Risk Patients Benefit Most From Eptifibatide February 21, 2006:715–8Given the potential for bleeding and the costs of treat-
ent, many physicians tailor therapy to the cohort of
atients most likely to derive benefit. The purpose of this
tudy was to determine whether the clinical characteristics
f patients in the ESPRIT trial could predict and discrim-
nate those most likely to benefit from eptifibatide therapy
n nonurgent coronary stenting.
ETHODS
atients. The ESPRIT trial was a multicenter, random-
zed, double-blind, placebo-controlled clinical trial con-
ucted in North America. The design and methods of the
rial have been previously described in detail (9). Briefly,
mong patients who were scheduled to undergo nonurgent
oronary stenting at 92 tertiary care centers in the U.S. and
anada, 2,064 were randomized to receive either eptifi-
atide or placebo. Patients with coronary artery disease
cheduled to undergo PCI with stent implantation without
lanned use of GP IIb/IIIa inhibitor therapy were included
n the study. The exclusion criteria were MI within 24 h
efore randomization, continuing chest pain triggering
rgent referral for PCI, previous stent implantation at the
arget lesion, PCI within 90 days, treatment with GP
Ib/IIIa inhibitor or a thienopyridine in the 30 days before
andomization, stroke or transient ischemic attack within 30
ays before randomization, any history of hemorrhagic
troke, history of bleeding diathesis or evidence of abnormal
leeding within 30 days before randomization, major sur-
ery within the previous 6 weeks; uncontrolled hypertension
ith a systolic blood pressure 200 mm Hg or diastolic
110 mm Hg, documented thrombocytopenia with a
latelet count 100  109/l, or a serum creatinine 350
mol/l.
reatment. Patients were assigned to receive either pla-
ebo or eptifibatide in a one-to-one distribution. After
retreatment with aspirin and a thienopyridine on the
ay of randomization, the study drug was started imme-
iately before initiation of PCI. Eptifibatide (Integrilin,
illennium Pharmaceuticals, Cambridge, Massachusetts,
nd Schering-Plough Research Institute, Kenilworth, New
ersey) was administered as two boluses followed by a
aintenance infusion. The first bolus of 180 g/kg was
mmediately followed by initiation of 2 g/kg/min con-
inuous infusion for 18 to 24 h. A second bolus of 180
Abbreviations and Acronyms
CK-MB  creatine kinase-MB
ESPRIT  Enhanced Suppression of the Platelet IIb/
IIIa Receptor with Integrilin Therapy trial
GP  glycoprotein
MI  myocardial infarction
PCI  percutaneous coronary intervention
STEMI  ST-segment elevation myocardial infarction
Tn-T  troponin-Tg/kg was given 10 min after the first bolus. All patients 5eceived weight-adjusted heparin with a target activated
lotting time of 200 to 300 s. Local standards were used
uring PCI, and any approved stent could be implanted.
isk profile. For the purpose of this analysis, the patients
andomized in the ESPRIT trial were categorized into high or
ow risk. High risk was defined as any patient who had at least
ne of the following characteristics:75 years of age, diabetes
diet or medically treated), baseline creatine kinase-MB (CK-
B) above the upper limit of normal (ULN), baseline
roponin-T (Tn-T) greater than the ULN, primary reason
or admission of unstable angina within 48 h of random-
zation or ST-segment elevation mycardial infarction
STEMI) within the previous seven days. A patient with
one of these characteristics was considered low risk. A
atient who met the low risk criteria but had missing
aseline cardiac biomarkers (CK-MB and/or Tn-T) also
as considered low risk.
The composite of death and MI at 30 days and 12
onths was evaluated as the end point for this analysis. End
oint MI included those identified by elevation of CK-MB
o at least three times the ULN on two occasions measured
h apart and those confirmed as MI after adjudication by a
linical events committee. The latter required corroboration
n the form of a clinical syndrome consistent with MI and
upportive electrocardiographic or cardiac marker data.
ollow-up of end point clinical events was obtained by
hysician visit or phone contact at 30 days and 12 months
fter randomization. More than 95% of the patients had
380 days of follow-up.
tatistical analysis. Categorical factors are expressed as
ercentages and continuous as medians with 25th and 75th
ercentiles. Differences in baseline factors for the two risk
roups are compared using a Pearson chi-square test for
ategorical factors and a Wilcoxon rank-sum test for
ontinuous. Event rates are expressed using Kaplan-
eier rates. Cox proportional hazard modeling tech-
iques were used to test the association between risk class
nd death or MI. A univariable model tested risk classi-
cation alone. A model also including randomized treat-
ent and the interaction of risk group with treatment
ested whether the treatment effect varied for the two risk
roups. Analyses were performed on an intention-to-
reat principle using SAS version 8.2 (SAS Institute,
ary, North Carolina).
A p value of 0.05 or less was considered statistically
ignificant.
ESULTS
mong the 2,064 ESPRIT trial patients, 1,018 (49.3%) and
,045 (50.6%) were categorized as high and low risk
espectively. One patient was excluded owing to missing
iabetes information. Baseline characteristics were simi-
ar in both groups except for more hypertension (63% vs.
5%, respectively), peripheral vascular disease (8.2% vs.
.2%, respectively), prior history of stroke (5.5% vs. 3.2%,
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February 21, 2006:715–8 High-Risk Patients Benefit Most From Eptifibatideespectively), and female gender (33% vs. 22%, respec-
ively) in the high-risk than the low-risk group (Table 1)
f the 1,018 high-risk patients, 517 (50.8%) received
ptifibatide, as did 1,045 of the low-risk patients 522
50.0%) (Fig. 1).
Among the high-risk patients, the 30-day composite end
oint of death or MI occurred in 12.38% (95% confidence
nterval [CI] 9.49 to 15.26) of patients randomized to
lacebo and in 6.19% (95% CI 4.11 to 8.27) of those
andomized to eptifibatide (p  0.001), and in the low-risk
roup it occurred in 8.03% (95% CI 5.70 to 10.36) of the
lacebo patients and in 6.51% (95% CI 4.40 to 8.63) of the
ptifibatide patients (p  0.341).
able 1. Patient Baseline Characteristics
Characteristics
High Risk
n  1,018
Low Risk
n  1,045 p Value
edian age (yrs) 65 (55,74) 61 (53,78) 0.001
emale (%) 32.7 21.8 0.001
aucasian (%) 88.1 91.9 0.004
edian weight (kg) 85 (75,95) 84 (73,97) 0.559
revious MI (%) 30.9 32.2 0.524
revious PCI (%) 24.8 22.1 0.155
revious CABG (%) 10.4 10.0 0.785
iabetes (%) 40.9 0.3 0.001
ypertension (%) 62.6 55.0 0.001
yslipidemia (%) 56.1 60.1 0.069
eripheral vascular disease (%) 8.2 5.2 0.006
revious stroke (%) 5.5 3.2 0.009
igarette smoking (%) 0.001
Never 32.7 25.6
Former 44.3 50.7
Current 23.0 23.7
rimary reason for admission (%) 0.001
Stable angina 25.0 51.6
Unstable angina/NQWMI 54.0 35.3
Acute STEMI within 7 days 9.1 0.0
Positive functional study 7.1 11.0
Other anginal equivalent 2.4 2.1
reatment (%) 0.705
Placebo 49.2 50.0
Eptifibatide 50.8 50.0
ABG  coronary artery bypass grafting; MI  myocardial infarction; NQWMI 
on–Q-wave myocardial infarction; PCI  percutaneous coronary intervention;
TEMI  ST-segment elevation myocardial infarction.Figure 1. Flow of patients.At 12 months, the composite end point of death or MI
ccurred in 15.89% of placebo patients and 7.99% of
ptifibatide patients among the high-risk group (p 0.001)
nd in 9.02% of placebo and 8.11% of eptifibatide low-risk
atients (p  0.571) (Table 2). The effect of eptifibatide in
reventing death or MI was significantly higher among the
igh-risk group when compared to the low risk popula-
ion (p 0.032 for interaction test) (Fig. 2). The same
rend was seen at 30 days, but the interaction was not
tatistically significant (p  0.104). Multivariate analysis
howed that unstable angina or STEMI and abnormal
K-MB independently predicted death or MI at 30 days
r 12 months. Bleeding complications were higher in the
ptifibatide-treated patients but did not reach statistical
ignificance.
ISCUSSION
he acute benefits of eptifibatide have been established in a
umber of settings, including treatment of patients with
cute coronary syndromes and as adjunctive therapy for
atients undergoing PCI (10). The 6- and 12-month
ollow-up of patients in the ESPRIT trial shows the efficacy
f eptifibatide in coronary stenting to be statistically signif-
cant and clinically relevant (10,11). The absolute difference
n the incidence of the end points of death or MI between
ays 30 and 360 remained constant (11). This suggests a
enefit of therapy beyond what would be expected from the
rocedural antiplatelet effects of treatment.
There is only a limited amount of data available describ-
ng the relationship of clinical risk profile with degree of
able 2. Death or MI at 30 Days and 12 Months Among the
wo Risk Groups
Death or MI (95% CI)
30 Days 12 Months
igh risk (eptifibatide) 6.19% (4.11–8.27) 7.99% (5.64–10.34)
igh risk (placebo) 12.38% (9.49–15.26) 15.89% (12.67–19.10)
ow risk (eptifibatide) 6.51% (4.40–8.63) 8.11% (5.76–10.46)
ow risk (placebo) 8.03% (5.70–10.36) 9.02% (6.56–11.48)
I  confidence interval; MI  myocardial infarction.Figure 2. Survival from death or myocardial infarction to 12 months.
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High-Risk Patients Benefit Most From Eptifibatide February 21, 2006:715–8enefit from GP IIb/IIIa therapy during coronary interven-
ion. After classifying the patients randomized in the
SPRIT trial to high risk and low risk, we were able to
emonstrate an enhanced beneficial effect of GP IIb/IIIa
nhibition in the high-risk group compared with the low-
isk group. This fairly straightforward classification scheme
ay thus help direct therapy to those most likely to achieve
enefit.
Interestingly, patients who did not meet the high risk
riteria also demonstrated a trend favoring benefit from
ptifibatide therapy compared with placebo. However, the
avorable effect was not as strong as in the high-risk group
nd did not reach statistical significance.
Compared to the low risk group, more patients in the
igh-risk group had hypertension, peripheral vascular dis-
ase, and prior history of stroke. Statistical adjustment for
hese parameters would likely have demonstrated the favor-
ble effect of eptifibatide to be more pronounced in the
igh-risk patients compared with the low-risk group than
as observed in the study.
Despite consistent short and long term benefits of GP
Ib/IIIa blockade in patients undergoing PCI, widespread
se of these agents has not become standard. Initially,
nstitutional or physician concerns with procedural costs or
he potential for bleeding may have limited the use of this
lass of antiplatelet agents to “bail out” situations (where
fficacy has not been established) or in high-risk groups.
ubsequently, the approval of the direct thrombin inhibitor
ivalirudin, less expensive and easier to use than combina-
ion unfractionated heparin and GP IIb/IIIa inhibitors, may
ave further limited the widespread utilization of GP
Ib/IIIa inhibitors. The nearly 50% reduction in death or
I in high-risk patients at 30 days and 12 months in our
tudy should serve to abate these issues.
onclusions. Clinical outcomes of patients undergoing
lective PCI can be improved significantly through inhibi-
ion of the platelet GP IIb/IIIa receptor. This treatment
odality confers enhanced benefit among patients with aigh-risk clinical profile. Widespread and consistent use of
latelet GP IIb/IIIa inhibition remains standard in the care
f high-risk patients undergoing elective PCI.
eprint requests and correspondence:Dr. Joseph A. Puma, New
ork Methodist Hospital-Cornell Heart Center, 506 6th Street,
Buckley Pavilion, Brooklyn, New York 11215. E-mail:
oepuma1@aol.com.
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